Literature DB >> 12900143

On vaccine efficacy and reproduction numbers.

C P Farrington1.   

Abstract

We consider the impact of a vaccination programme on the transmission potential of the infection in large populations. We define a measure of vaccine efficacy against transmission which combines the possibly random effect of the vaccine on individual susceptibility and infectiousness. This definition extends some previous work in this area to arbitrarily heterogeneous populations with one level of mixing, but leads us to question the usefulness of the concept of vaccine efficacy against infectiousness. We derive relationships between vaccine efficacy against transmission, vaccine coverage and reproduction numbers, which generalize existing results. In particular we show that the projected reproduction number RV does not depend on the details of the vaccine model, only on its overall effect on transmission. Explicit expressions for RV and the basic reproduction number R0 are obtained in a variety of settings. We define a measure of projected effectiveness of a vaccination programme PE=1-(RV/R0) and investigate its relationship with efficacy against transmission and vaccine coverage. We also study the effective reproduction number Re(t) at time t. Monitoring Re(t) over time is an important aspect of programme surveillance. Programme effectiveness PE is less sensitive than RV or the critical vaccination threshold to model assumptions. On the other hand Re(t) depends on the details of the vaccine model.

Entities:  

Mesh:

Year:  2003        PMID: 12900143     DOI: 10.1016/s0025-5564(03)00061-0

Source DB:  PubMed          Journal:  Math Biosci        ISSN: 0025-5564            Impact factor:   2.144


  16 in total

1.  Design and Evaluation of Prophylactic Interventions Using Infectious Disease Incidence Data from Close Contact Groups.

Authors:  Yang Yang; Ira M Longini; M Elizabeth Halloran
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2006-05       Impact factor: 1.864

2.  EPIDEMIOLOGICAL CONSEQUENCES OF IMPERFECT VACCINES FOR IMMUNIZING INFECTIONS.

Authors:  F M G Magpantay; M A Riolo; M Domenech DE Cellès; A A King; P Rohani
Journal:  SIAM J Appl Math       Date:  2014       Impact factor: 2.080

3.  Vaccine impact in homogeneous and age-structured models.

Authors:  F M G Magpantay
Journal:  J Math Biol       Date:  2017-04-17       Impact factor: 2.259

4.  Vaccination games in prevention of infectious diseases with application to COVID-19.

Authors:  Jingwen Ge; Wendi Wang
Journal:  Chaos Solitons Fractals       Date:  2022-06-10       Impact factor: 9.922

5.  Pertussis immunity and epidemiology: mode and duration of vaccine-induced immunity.

Authors:  F M G Magpantay; M Domenech DE Cellès; P Rohani; A A King
Journal:  Parasitology       Date:  2015-09-04       Impact factor: 3.234

6.  A time-delayed SVEIR model for imperfect vaccine with a generalized nonmonotone incidence and application to measles.

Authors:  Isam Al-Darabsah
Journal:  Appl Math Model       Date:  2020-10-01       Impact factor: 5.129

Review 7.  Estimating influenza vaccine efficacy from challenge and community-based study data.

Authors:  Nicole E Basta; M Elizabeth Halloran; Laura Matrajt; Ira M Longini
Journal:  Am J Epidemiol       Date:  2008-10-29       Impact factor: 4.897

8.  Vaccination control of an epidemic model with time delay and its application to COVID-19.

Authors:  Shidong Zhai; Guoqiang Luo; Tao Huang; Xin Wang; Junli Tao; Ping Zhou
Journal:  Nonlinear Dyn       Date:  2021-05-28       Impact factor: 5.741

9.  The impact of model building on the transmission dynamics under vaccination: observable (symptom-based) versus unobservable (contagiousness-dependent) approaches.

Authors:  Keisuke Ejima; Kazuyuki Aihara; Hiroshi Nishiura
Journal:  PLoS One       Date:  2013-04-12       Impact factor: 3.240

Review 10.  Extracting key information from historical data to quantify the transmission dynamics of smallpox.

Authors:  Hiroshi Nishiura; Stefan O Brockmann; Martin Eichner
Journal:  Theor Biol Med Model       Date:  2008-08-20       Impact factor: 2.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.